Stevanato Group Future Growth
Future criteria checks 3/6
Stevanato Group is forecast to grow earnings and revenue by 20.6% and 8.7% per annum respectively. EPS is expected to grow by 19.6% per annum. Return on equity is forecast to be 11.1% in 3 years.
Key information
20.6%
Earnings growth rate
19.6%
EPS growth rate
| Life Sciences earnings growth | 15.9% |
| Revenue growth rate | 8.7% |
| Future return on equity | 11.1% |
| Analyst coverage | Good |
| Last updated | 14 Feb 2025 |
Recent future growth updates
Stevanato Group S.p.A. Just Missed Earnings - But Analysts Have Updated Their Models
Nov 08
Stevanato Group S.p.A. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
May 12Recent updates
Calculating The Fair Value Of Stevanato Group S.p.A. (NYSE:STVN)
Feb 01Stevanato Group S.p.A. (NYSE:STVN) Not Lagging Market On Growth Or Pricing
Dec 09Stevanato: Supportive Biopharmaceutical And Diagnostic Segment And Destocking Improvement
Nov 13Stevanato Group's (NYSE:STVN) Anemic Earnings Might Be Worse Than You Think
Nov 12Stevanato Group S.p.A. Just Missed Earnings - But Analysts Have Updated Their Models
Nov 08We Think Stevanato Group (NYSE:STVN) Is Taking Some Risk With Its Debt
Oct 23Is Stevanato Group S.p.A. (NYSE:STVN) Worth US$19.3 Based On Its Intrinsic Value?
Aug 21Stevanato Group S.p.A. (NYSE:STVN) Looks Just Right With A 28% Price Jump
Jul 25Does Stevanato Group (NYSE:STVN) Have A Healthy Balance Sheet?
Jul 23Stevanato: Destock Pressures, Long-Term Upside
May 29Stevanato Group S.p.A. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
May 12Stevanato Group S.p.A.'s (NYSE:STVN) Share Price Matching Investor Opinion
May 07Stevanato Group's (NYSE:STVN) Solid Earnings May Rest On Weak Foundations
Mar 15Stevanato: Destocking And Valuation Risk (Rating Downgrade)
Mar 12Stevanato: Guidance Reiterated And Supportive Revenue Growth
Nov 22Stevanato: Secular Tailwinds In Biologics Support Downstream Demand
Sep 15Stevanato Group: Undeniable Quality, But Lacking Upside
Jun 14Stevanato Group and Transcoject to provide pre-fillable syringe polymer options for pharma
Jan 24Stevanato Group Non-GAAP EPS of $0.14 beats by $0.01, revenue of $245.3M in-line
Nov 08Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2027 | 1,482 | N/A | 136 | 355 | 2 |
| 12/31/2026 | 1,307 | 180 | 71 | 312 | 9 |
| 12/31/2025 | 1,178 | 142 | 22 | 265 | 11 |
| 12/31/2024 | 1,096 | 119 | -113 | 195 | 11 |
| 9/30/2024 | 1,094 | 115 | -187 | 122 | N/A |
| 6/30/2024 | 1,088 | 123 | -257 | 138 | N/A |
| 3/31/2024 | 1,083 | 136 | -276 | 140 | N/A |
| 12/31/2023 | 1,085 | 146 | -337 | 105 | N/A |
| 9/30/2023 | 1,057 | 149 | -268 | 155 | N/A |
| 6/30/2023 | 1,031 | 147 | -216 | 117 | N/A |
| 3/31/2023 | 1,010 | 143 | -182 | 135 | N/A |
| 12/31/2022 | 984 | 143 | -140 | 103 | N/A |
| 9/30/2022 | 924 | 139 | -114 | 99 | N/A |
| 6/30/2022 | 893 | 122 | -78 | 121 | N/A |
| 3/31/2022 | 863 | 125 | -13 | 133 | N/A |
| 12/31/2021 | 844 | 134 | 20 | 133 | N/A |
| 9/30/2021 | 818 | 123 | 32 | 139 | N/A |
| 6/30/2021 | 761 | 121 | 72 | 171 | N/A |
| 3/31/2021 | 718 | 108 | 77 | 171 | N/A |
| 12/31/2020 | 662 | 79 | 60 | 156 | N/A |
| 12/31/2019 | 537 | 39 | -31 | 43 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: STVN's forecast earnings growth (20.6% per year) is above the savings rate (2.8%).
Earnings vs Market: STVN's earnings (20.6% per year) are forecast to grow faster than the US market (14.5% per year).
High Growth Earnings: STVN's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: STVN's revenue (8.7% per year) is forecast to grow slower than the US market (8.9% per year).
High Growth Revenue: STVN's revenue (8.7% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: STVN's Return on Equity is forecast to be low in 3 years time (11.1%).
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/16 12:07 |
| End of Day Share Price | 2025/02/14 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Stevanato Group S.p.A. is covered by 15 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Ishan Majumdar | Baptista Research |
| Curtis Moiles | BNP Paribas Exane |
| Derik de Bruin | BofA Global Research |